Visual Stimulation Through Video Therapy to Enhance Lower Limb Motor Recovery After Stroke (SI-VI-MI)
Use of Intensive Visual Stimulation Through Video Therapy to Enhance Lower Limb Motor Recovery After Stroke (SIVIMI). A Single-Center Pilot Study Using a Single-Case Experimental Design (SCED)
This pilot study evaluates video therapy for lower limb motor recovery after stroke, an approach remains insufficiently documented.
This single-center pilot study uses a Single-Case Experimental Design (SCED) to evaluate the effects of intensive video therapy combined with conventional rehabilitation in patients with subacute or chronic post-stroke hemiparesis. Twelve participants will be included and allocated to different baseline durations according to a multiple-baseline SCED design.
The primary outcome is functional mobility, assessed using the Timed Up and Go (TUG) test, measured repeatedly throughout baseline, intervention, and follow-up phases.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Stroke frequently results in persistent lower limb motor impairment affecting gait and functional mobility (1-2). While video-based therapies have shown proof of concept for upper limb rehabilitation after stroke, their effectiveness for lower limb motor recovery remains insufficiently documented (3-5).
This study is a single-center pilot trial using a Single-Case Experimental Design (SCED) with multiple baseline durations, chosen to account for the high interindividual variability observed in subacute and chronic post-stroke patients undergoing rehabilitation (6). This design allows each participant to serve as their own control through repeated measurements over time (6).
Participants are included between 1 month and 1 year post-stroke while receiving inpatient or outpatient rehabilitation in a Physical Medicine and Rehabilitation department. All participants initially undergo a control phase combining standardized rehabilitation with sham video therapy (placebo condition). The duration of this baseline phase is randomized (1, 2, or 3 weeks) across participants.
The experimental phase consists of 5 weeks of intensive video therapy added to usual care, with five sessions per week. A post-intervention sham phase is followed by a follow-up period lasting up to 21 weeks post-intervention, with repeated assessments conducted at weeks 13, 17, and 21 to evaluate maintenance of treatment effects.
The primary objective is to evaluate changes in functional mobility, assessed using repeated measurements of the Timed Up and Go test. Secondary objectives include evaluation of gait endurance, motor impairment, muscle tone, balance, and quality of life
.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Etienne OJARDIAS, Dr
- Numéro de téléphone: 33 0477127018
- E-mail: Etienne.Ojardias@chu-st-etienne.fr
Lieux d'étude
-
-
-
Saint-Etienne, France, 42100
- Recrutement
- Service de Médecine Physique et réadaptation
-
Sous-enquêteur:
- Hugo BESSAGUET, MD
-
Sous-enquêteur:
- Julia TOULY, MD
-
Contact:
- Diana RIMAUD, PhD
- Numéro de téléphone: 33 04 77 12 04 67
- E-mail: Diana.Rimaud@chu-st-etienne.fr
-
Sous-enquêteur:
- Pascal GIRAUX, MD, PhD
-
Chercheur principal:
- Etienne OJARDIAS, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- - First or recurrent hemispheric ischemic or hemorrhagic stroke in the subacute or chronic phase (from 1 month to 1 year post-stroke).
- Currently receiving rehabilitation care in a Physical Medicine and Rehabilitation (PM&R) department
- Able to walk 3 meters back and forth, with or without an assistive device.
- Provided informed consent, signed jointly with the investigator.
Exclusion Criteria:
- - Severe hemispatial neglect.
- Severe spasticity impairing proper positioning (Modified Ashworth Scale > 3).
- Severe general disabling medical conditions.
- Associated cerebellar syndrome.
- Major comprehension disorders, psychiatric illness, or cognitive impairments that could interfere with study participation.
- Participants under full legal guardianship (tutorship).
- Pregnant or breastfeeding women.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Sequence 1
1 week of sham videotherapy , 5 weeks of intervention (active videotherapy) , 2 weeks of sham videotherapy.
|
During active videotherapy sessions, the image inversion program is activated, superimposing movements of the non-paretic limb onto the paretic limb, which is hidden behind the screen.
Participants are instructed to imagine and attempt to reproduce the observed movements using their paretic limb.
Each participant completes 25 sessions over 5 weeks (5 sessions per week).
During sham videotherapy sessions, participants are seated facing the IVS4 screen without activation of the image inversion program.
Participants perform lower limb movements while directly viewing their paretic limb in real time on the screen, corresponding to an action observation condition without visual illusion.
|
|
Expérimental: Sequence 2
2 weeks of sham videotherapy , 5 weeks of intervention (active videotherapy) , 1 weeks of sham videotherapy.
|
During active videotherapy sessions, the image inversion program is activated, superimposing movements of the non-paretic limb onto the paretic limb, which is hidden behind the screen.
Participants are instructed to imagine and attempt to reproduce the observed movements using their paretic limb.
Each participant completes 25 sessions over 5 weeks (5 sessions per week).
During sham videotherapy sessions, participants are seated facing the IVS4 screen without activation of the image inversion program.
Participants perform lower limb movements while directly viewing their paretic limb in real time on the screen, corresponding to an action observation condition without visual illusion.
|
|
Expérimental: Sequence 3
3 weeks of sham videotherapy and 5 weeks of intervention (active videotherapy) ,
|
During active videotherapy sessions, the image inversion program is activated, superimposing movements of the non-paretic limb onto the paretic limb, which is hidden behind the screen.
Participants are instructed to imagine and attempt to reproduce the observed movements using their paretic limb.
Each participant completes 25 sessions over 5 weeks (5 sessions per week).
During sham videotherapy sessions, participants are seated facing the IVS4 screen without activation of the image inversion program.
Participants perform lower limb movements while directly viewing their paretic limb in real time on the screen, corresponding to an action observation condition without visual illusion.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
1. Timed Up and Go Test (TUG)
Délai: 5-week
|
Time required to stand up from a chair, walk 3 meters, return, and sit down (in seconds)
|
5-week
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
2. 2-Minute Walk Test (2MWT)
Délai: Weeks 1, 2, 3, 8, 13, 17, and 21
|
Walking endurance assessed by the distance walked in 2 minutes (in meters).
|
Weeks 1, 2, 3, 8, 13, 17, and 21
|
|
3. Fugl-Meyer Assessment - Lower Limb Section
Délai: Weeks 1, 2, 3, 8, 13, 17, and 21
|
Motor function of the hemiplegic lower limb, assessed with the Fugl-Meyer scale (score from 0 to 34)
|
Weeks 1, 2, 3, 8, 13, 17, and 21
|
|
4. Muscle Strength - Foot Dorsiflexors and extensors
Délai: Weeks 1, 2, 3, 8, 13, 17, and 21
|
Muscle strength of the foot dorsiflexors and extensors, measured in Newtons using a handheld dynamometer
|
Weeks 1, 2, 3, 8, 13, 17, and 21
|
|
5. Muscle Tone - Modified Ashworth Scale (MAS)
Délai: Weeks 1, 2, 3, 8, 13, 17, and 21
|
Spasticity assessment of dorsiflexors and extensors of the foot using the Modified Ashworth Scale (score 0-5).
|
Weeks 1, 2, 3, 8, 13, 17, and 21
|
|
6. Muscle Tone - Modified Tardieu Scale
Délai: Weeks 1, 2, 3, 8, 13, 17, and 21
|
Spasticity assessment of dorsiflexors and extensors of the foot using the Modified Tardieu Scale (score 0-5).
|
Weeks 1, 2, 3, 8, 13, 17, and 21
|
|
7. Postural Balance - PASS (Postural Assessment Scale for Stroke Patients)
Délai: Weeks 1, 2, 3, 8, 13, 17, and 21
|
Balance ability assessed using the PASS scale (score 0-36).
|
Weeks 1, 2, 3, 8, 13, 17, and 21
|
|
8. Quality of Life - Stroke Specific Quality of Life Scale (SS-QOL)
Délai: Weeks 1, 2, 3, 8, 13, 17, and 21
|
Quality of life assessed with the SS-QOL scale (score range: 49-245).
|
Weeks 1, 2, 3, 8, 13, 17, and 21
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Etienne OJARDIAS, Dr, Centre Hospitalier Universitaire de Saint Etienne
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- 25CH169
- 2025-A02102-47 (Autre identifiant: ANSM)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .